Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
Clinical trial NCT02906059 · COMPLETED
Trial details
- NCT number
- NCT02906059
- Sponsor
- NYU Langone Health
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2020-03-12
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.